Fractyl Health Reports Q1 Net Income of $9.2M; Nasdaq Non-Compliance Noted
Fractyl Health reported a net income of $9.2 million for the first quarter ended March 31, 2026, a substantial improvement from a net loss of $23.7 million in the prior year, primarily driven by a $30.1 million positive change in the fair value of warrant liabilities. The company received a Nasdaq notice for non-compliance with the minimum bid price rule and appointed Lara Smith Weber as its new CFO. Fractyl Health also made progress in its clinical programs, completing randomization for the Revita REMAIN-1 Pivotal Cohort and receiving CTA authorization for Rejuva RJVA-001 in the Netherlands, though it noted substantial doubt about its ability to continue as a going concern beyond early 2027 without additional funding.
Key Highlights
- Q1 2026 Net Income was $9.2 million, compared to a net loss of $23.7 million in Q1 2025.
- Change in fair value of warrant liabilities resulted in a $30.1 million income in Q1 2026.
- Cash and cash equivalents were $63.2 million as of March 31, 2026.
- Received Nasdaq minimum bid price non-compliance notice on March 13, 2026.
- Lara Smith Weber was appointed Chief Financial Officer, effective January 12, 2026.
- Revita REMAIN-1 Pivotal Cohort randomization completed in February 2026; topline data expected early Q4 2026.
- Rejuva RJVA-001 received CTA authorization in the Netherlands in April 2026 for a Phase 1/2 first-in-human study.
- Management believes existing cash will fund operations into early 2027, but not for 12 months from filing date, raising substantial doubt about going concern.
Price Impact
More from GUTS